Maze Therapeutics’ (MAZE) “Buy” Rating Reiterated at HC Wainwright

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They currently have a $110.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 307.56% from the stock’s current price.

A number of other equities research analysts also recently weighed in on MAZE. Citigroup initiated coverage on Maze Therapeutics in a research report on Wednesday. They set a “buy” rating and a $50.00 target price on the stock. TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Monday. Finally, Wedbush reiterated an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $63.40.

Maze Therapeutics Stock Performance

MAZE stock traded down $1.10 on Thursday, reaching $26.99. 67,082 shares of the company were exchanged, compared to its average volume of 658,541. The firm has a market capitalization of $1.50 billion, a PE ratio of -10.72 and a beta of 2.17. Maze Therapeutics has a 12 month low of $21.95 and a 12 month high of $53.65. The stock’s fifty day moving average price is $27.18 and its 200 day moving average price is $29.17. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). On average, research analysts anticipate that Maze Therapeutics will post -2.72 EPS for the current fiscal year.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at $445,680.62. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total value of $907,031.29. Following the transaction, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at approximately $477,189.79. The trade was a 65.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 191,459 shares of company stock valued at $5,263,539. Corporate insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC boosted its holdings in shares of Maze Therapeutics by 42.8% in the 2nd quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock worth $580,000 after acquiring an additional 5,822 shares in the last quarter. Frazier Life Sciences Management L.P. grew its stake in shares of Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock valued at $150,182,000 after purchasing an additional 465,641 shares during the last quarter. AXQ Capital LP increased its holdings in shares of Maze Therapeutics by 114.1% in the second quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock valued at $453,000 after purchasing an additional 8,098 shares in the last quarter. Braidwell LP bought a new position in Maze Therapeutics in the 2nd quarter worth approximately $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Maze Therapeutics by 4,054.3% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock worth $529,000 after purchasing an additional 17,312 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically driven diseases. The company combines human genetics, functional genomics and drug discovery technologies through its Maze Compass platform to identify disease mechanisms and develop therapies designed to address the underlying causes of disease.

Maze’s lead program, MZE001, is an oral small-molecule inhibitor of glycogen synthase being developed for Pompe disease, a rare inherited disorder in which glycogen accumulates in muscles and other tissues.